OncoTargets and Therapy (Oct 2021)
Correlation Between Thymoma and Soluble Interleukin-2 Receptor Expression in a Patient with Good Syndrome
Abstract
Haruka Kitano, Fumihiro Yamaguchi, Kenji Atarashi, Mina Hiraiwa, Yo Shiratori, Shota Onozaki, Yusuke Shikama Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, 227-8501, JapanCorrespondence: Fumihiro YamaguchiDepartment of Respiratory Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa, 227-8501, JapanTel +81-45-973-2848Email [email protected]: Good syndrome is a rare condition characterized by the presence of thymoma in combination with adult-onset hypogammaglobulinemia. Immunological features of Good syndrome include various immunodeficiencies accompanied with hypogammaglobulinemia. In patients with thymoma, paraneoplastic syndromes including hypogammaglobulinemia worsen the prognosis. We herein describe a patient with advanced-stage type A thymoma who was effectively treated with chemotherapy and exhibited a parallel decrease in the serum level of soluble interleukin-2 receptor (sIL-2R), which depends on cellular immunity. The present case suggests the efficacy of sIL-2R as a potential prognostic biomarker in a subset of patients with Good syndrome.Keywords: thymoma, hypogammaglobulinemia, Good syndrome, soluble interleukin-2 receptors